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Background: The aim of this study was to optimize the different process parameters including 
pressure, temperature, and polymer concentration, to produce fine small spherical particles with 
a narrow particle size distribution using a supercritical antisolvent method for drug encapsula-
tion. The interaction between different process parameters was also investigated.
Methods and results: The optimized process parameters resulted in production of 
nanoencapsulated paracetamol in L-polylactide with a mean diameter of approximately 300 nm 
at 120 bar, 30°C, and a polymer concentration of 16 ppm. Thermogravimetric analysis illustrated 
the thermal characteristics of the nanoparticles. The high electrical charge on the surface of 
the nanoparticles caused the particles to repel each other, with the high negative zeta potential 
preventing flocculation.
Conclusion: Our results illustrate the effect of different process parameters on particle size 
and morphology, and validate results obtained via RSM statistical software. Furthermore, the 
in vitro drug-release profile is consistent with a Korsmeyer–Peppas kinetic model.
Keywords: supercritical, antisolvent, encapsulation, nanoparticles, biodegradable polymer, 
optimization, drug delivery
Introduction
The morphology, particle size, and distribution of nanoparticles determine drug 
delivery and bioavailability using these systems, because these characteristics improve 
the drug solubility in the aqueous media of the body. The pharmaceutical industry needs 
to produce smaller nanoencapsulated drugs with a narrow size distribution to improve 
drug delivery using needle-free injections, dry powder inhalers, and controlled-release 
devices. Using supercritical carbon dioxide (ScCO2) as a medium in nanoencapsulation 
processes is a practical choice, because most pharmaceutical compounds are thermally 
labile and thus encapsulated drugs should be free from any organic solvent residues and 
artifacts. In contrast with conventional techniques, the advantages of ScCO2 techniques 
are their single-step nature, a mild operating temperature, and a very narrow particle 
size distribution with controlled morphology.1 Supercritical fluid technologies are 
clean and effective methods for drug encapsulation which enable the production of 
small particle sizes with a narrow distribution, allowing for greater flexibility of drug 
  administration. Furthermore, increasing bioavailability decreases the drug dosage neces-
sary and enables controlled release over a sustained period of time.2–8 Small-sized drugs 
can accelerate towards target organs and be distributed evenly throughout the body.9–13 
In this study, paracetamol was encapsulated in a biodegradable L-polylactide polymer 
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antisolvent technique. We investigated the effect of these dif-
ferent process parameters on particle size and morphology. 
The optimum particle size was determined via RSM statistical 
software and confirmed by scanning electron microscopy.
Methods and materials
Poly L-lactic acid (intensive viscosity 2.0 dL/g) and high-
pressure liquid chromatography grade methylene chloride 
were obtained from Sigma-Aldrich (St Louis, MO). Paraceta-
mol (99.9%) was obtained from the Faculty of Medicine and 
Health Science, University Putra Malaysia. High-pressure 
liquid chromatography grade acetone was obtained from 
Fisher Scientific (Leicestershire, UK). Purified grade carbon 
dioxide is used as the supercritical fluid.
Preparation of nanoparticles
Supercritical CO2 was pumped into a high-pressure vessel 
(490 mL) at specific gas density. The solute was sprayed by 
a high-pressure pump (SCF P-50A; Thar, Pittsburgh, PA) 
through a 2 µm diameter nozzle. The solvent diffused rapidly 
from the solution droplets into the bulk supercritical fluid, 
precipitating the solute. Analysis of variance was performed 
using RSM software (v6; Maitland, FL). Optimization of 
particle size was obtained by varying the process condi-
tions. The various process parameters, including pressure, 
temperature, and polymer concentration used for particle 
nanoencapsulation are summarized in Table 1. The operating 
conditions were then kept constant while varying the other 
process parameters, as shown in Table 2.
characterization
scanning electron microscopy
Scanning electron microscopy (S-3400N; Hitachi, Tokyo, 
Japan) was used to characterize the morphology and size of 
the nanoencapsulated particles. Each sample was adhered to 
adhesive carbon tape on an aluminum stub and coated with 
gold palladium (Emitech K550X; Quorum Technologies 
Ltd, West Sussex, UK) at 35 mA for 2 minutes in a vacuum 
equal to 1 × 10−4 bar.
Thermogravimetric analysis
Thermogravimetric analysis (model TGA/SDTA851; Mettler-
Toledo, Columbus, OH) was used to determine weight loss 
as a function of incremental temperature. Analysis was 
performed by increasing the temperature gradually from 
50°C up to 600°C at a rate of 5°C/min and purging the gas 
with nitrogen at a flow rate of 20 mL/min.
Zeta potential
A ZEN 2600 Zetasizer (Malvern Instruments, Worcestershire, 
UK) with laser diffractometry was used to characterize the 
zeta potential of the encapsulated paracetamol. A nanoparticle 
sample weighing 1.5 mg was suspended in 5 mL of distilled 
water. The mean value from 20 successive readings was 
taken as the zeta potential of the paracetamol-L-polylactide 
nanoparticles.
In vitro drug release
The paracetamol released into the phosphate-buffered saline 
medium was analyzed using ultraviolet-visible spectrometry 
(Model 1650-PC; Shimadzu, Kyoto, Japan) at 243 nm. 
Nanoencapsulated paracetamol 25 mg was placed into 50 mL 
of phosphate-buffered saline (pH 7.4) containing sodium 
azide 0.025%. The sample was placed in a shaking incuba-
tor maintained at 50 rpm and 37°C. Aliquots of 2 mL were 
removed from the 50 mL suspension on various days up to 
30 days, and the volume lost was immediately replaced with 
fresh phosphate-buffered saline.
Results and discussion
The significant effects constitute the model. The F-value in 
the model was shown to be significant (F , 0.05) for A, B, 
C, B2, AC, AB, and BC (where A, B, C are temperature, 
pressure, and concentration). The following RSM equation 
was fitted to the response variable (particle size) and three 
independent variables, ie, temperature (A), pressure (B), and 
concentration (C):
Particle size = +7420.81097 + (22.78675 × A) − (10
1.23872 × B) − (251.88633 × Conc) + (1.86604 × A2) + 
(0.87703 × B 2) + (8.27705 × C 2) − (1.85212 × A × B) + 
(5.22151 × A × C) − (1.95945 × B × C).
The effect of density on particle size is shown in 
Figure 1. Enhancing supercritical fluid density decreased 
the particle size. The effect of temperature on particle size 
Table 1 Variable process parameters
Process parameters Value
Pressure (bar) 80, 90, 100, 110, 120
Temperature (°c) 30, 35, 40, 45, 50, 55
Polymer concentration (mg/mL) 12, 16, 20, 24, 28
Table 2 Fixed process parameters
Process parameters Value
cO2 flow rate (mL/min) 15
Feed flow rate (mL/min) 1.75
Feed delivery (mL) 20
ratio of DcM/acetone 3.2
Paracetamol concentration (mg/mL) 0.5International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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was more pronounced at low pressure. The effect of con-
centration on particle size was different, in that particle 
size was influenced simultaneously by the degree of super 
saturation and by the initial concentration. Therefore, it 
is crucial to adjust the initial polymer concentration. The 
chemical potential differences between the fluid and solid 
phases during the supercritical antisolvent process are the 
driving force for the phase transition, and thus, crystalliza-
tion. These differences depend on solute activity in the solu-
tion at equilibrium. Phase transition occurs spontaneously 
when there is a negative change in the chemical potential, 
whereas phase transition is made thermodynamically 
impossible by a positive change in the free energy. In the 
thermodynamic equilibrium state, the change in free energy 
is zero, as follows:
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where µ3* is the chemical potential at equilibrium, R is the 
Boltzman constant, γ3 is the fugacity (activity) coefficient 
of the solute at a given concentration χ3, and γ3* is the 
fugacity (activity) coefficient of the solute at equilibrium 
concentration, χ3*.
The activity coefficient is a function of the pressure and 
temperature in a supercritical fluid. Based on this   equation, 
it is clear that the presence of CO2 antisolvent dilutes the 
  mixture and decreases the mole fraction of the solute, 
and thus reduces the chemical potential. Furthermore, the 
presence of the CO2 antisolvent significantly decreases the 
equilibrium concentration (χ3*). In addition, super saturation 
in the bulk reactor affects particle growth. The nucleation rate 
determines both mean particle size and also the total number 
of particles, and the chemical potential difference is clarified 
in terms of super saturation, (S), as follows:
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The super saturation ratio is the solute concentration: 
solubility ratio or the super saturation concentration. On the 
other hand, super saturation is a proportion of the degree by 
which the solute concentration in the solution exceeds the 
equilibrium concentration at a specified temperature and 
pressure. If the concentrations of a nonvolatile solute are 
very low (typically less than 10−4 mole fraction), the ratio of 
the fugacity coefficients is approximately equal to 1 and the 
ratio of supersaturation is equal to the ratio of concentration 
as follows:
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where X3 is the mole fraction of solvent.
Based on both statistical data and scanning electron 
microscopic images, the optimum design point is 120 bar, 
30°C, and a polymer concentration of 16 ppm. Scanning 
electron microscopic images of products produced at tem-
peratures below 45°C showed fine spherical particles at all 
pressures tested. The effect of density on particle size and 
morphology is shown in Figure 2. The scanning electron 
microscopic images validate the RSM software results. The 
thermal stability of nanoencapsulated paracetamol inside the 
L-polylactide polymer was investigated by thermogravimet-
ric analysis at 120 bar, 30°C, and a polymer concentration of 
16 ppm. From Figure 3, it is evident that the temperature for 
maximum weight loss of paracetamol from the nanoparticles 
shifted to 32°C due to the L-polylactide polymer nanolayer 
covering the paracetamol. Furthermore, the thermogram 
of nanoencapsulated paracetamol inside L-polylactide was 
similar to that for pure L-polylactide due to the higher ratio 
of pure polymer in the solute.
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Figure 2 scanning electron microscopic images of nanoencapsulated paracetamol inside L-polylactide at different process parameters.
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Figure 3 Thermogravimetric analysis of pure paracetamol, pure L-polylactide, and encapsulated paracetamol inside L-polylactide.
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Figure 4 Zeta potential distribution graph of nanoencapsulated paracetamol inside L-polylactide.
Notes: The nanoparticles had a large negative zeta potential (−33 ± 3 mV) as shown in Figure 4 due to the presence of carboxyl end groups of the L-polylactide chain. 
Sustained release of paracetamol in phopshate-buffered saline was investigated over 4 weeks. The first burst happened after 1 week and the cumulative paracetamol release 
versus time are shown in Figure 5.International Journal of Nanomedicine
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The kinetics were fitted to a Korsmeyer–Peppas model 
as follows:
 
M
M
K
t
∞
= t
n
  (5)
where MM t/ ∞  is the fraction of paracetamol release at time 
t, and k is a constant indicating release rate. The slope of 
the plot indicates the release exponent, n (n = 3.027). This 
shows that the rate of drug release is independent of time 
and controlled by a swelling mechanism.
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Figure 5 In vitro release profile of paracetamol encapsulated in L-polylactide based 
on the Korsmeyer–Peppas model.
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